Abstract
Over the past two decades metabotropic glutamate (mGlu) receptor ligands have been investigated for their potential therapeutic effects in different disorders of the central nervous system (CNS), including anxiety, depression, schizophrenia, and neurodegenerative diseases. In addition, it has been widely demonstrated that mGlu receptors are able to modulate pain transmission both in inflammatory and neuropathic pain models. A large number of preclinical studies combining the use of selective ligands with the knockout strategy have revealed more details about the role of the different mGlu receptor subtypes in the modulation of pain information. This review will address the role of mGlu receptors in pain sensitivity focusing on different strategies to achieve pain control by targeting specific mGlu receptor subtypes. Specifically, pharmacological interventions aimed at inhibiting group I mGlu receptor-mediated signaling and/or potentiating groups II and III mGlu receptor signaling together with an epigenetic approach leading to an increased expression of mGlu2 receptors will be discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 28-34 |
| Number of pages | 7 |
| Journal | Current Opinion in Pharmacology |
| Volume | 12 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 2012 |
Fingerprint
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
Cite this
Metabotropic glutamate receptors and the control of chronic pain. / Chiechio, Santina; Nicoletti, Ferdinando.
In: Current Opinion in Pharmacology, Vol. 12, No. 1, 02.2012, p. 28-34.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metabotropic glutamate receptors and the control of chronic pain
AU - Chiechio, Santina
AU - Nicoletti, Ferdinando
PY - 2012/2
Y1 - 2012/2
N2 - Over the past two decades metabotropic glutamate (mGlu) receptor ligands have been investigated for their potential therapeutic effects in different disorders of the central nervous system (CNS), including anxiety, depression, schizophrenia, and neurodegenerative diseases. In addition, it has been widely demonstrated that mGlu receptors are able to modulate pain transmission both in inflammatory and neuropathic pain models. A large number of preclinical studies combining the use of selective ligands with the knockout strategy have revealed more details about the role of the different mGlu receptor subtypes in the modulation of pain information. This review will address the role of mGlu receptors in pain sensitivity focusing on different strategies to achieve pain control by targeting specific mGlu receptor subtypes. Specifically, pharmacological interventions aimed at inhibiting group I mGlu receptor-mediated signaling and/or potentiating groups II and III mGlu receptor signaling together with an epigenetic approach leading to an increased expression of mGlu2 receptors will be discussed.
AB - Over the past two decades metabotropic glutamate (mGlu) receptor ligands have been investigated for their potential therapeutic effects in different disorders of the central nervous system (CNS), including anxiety, depression, schizophrenia, and neurodegenerative diseases. In addition, it has been widely demonstrated that mGlu receptors are able to modulate pain transmission both in inflammatory and neuropathic pain models. A large number of preclinical studies combining the use of selective ligands with the knockout strategy have revealed more details about the role of the different mGlu receptor subtypes in the modulation of pain information. This review will address the role of mGlu receptors in pain sensitivity focusing on different strategies to achieve pain control by targeting specific mGlu receptor subtypes. Specifically, pharmacological interventions aimed at inhibiting group I mGlu receptor-mediated signaling and/or potentiating groups II and III mGlu receptor signaling together with an epigenetic approach leading to an increased expression of mGlu2 receptors will be discussed.
UR - http://www.scopus.com/inward/record.url?scp=84857238962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857238962&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2011.10.010
DO - 10.1016/j.coph.2011.10.010
M3 - Article
VL - 12
SP - 28
EP - 34
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
SN - 1471-4892
IS - 1
ER -